 Dyne Therapeutics Inc NASDAQ: DYN has announced new preclinical data from its myotonic dystrophy type 1 DM1 program, including results demonstrating sustained knockdown of toxic human nuclear DMPK RNA, the genetic basis of the disease. Data were presented at the American Society of Gene Cell Therapy Annual Meeting. 